Switching to a 2-drug regimen of dolutegravir plus rilpivirine maintained viral suppression among people on successful 3- or 4-drug antiretroviral therapy in a pair of Phase 3 clinical trials, according to an announcement last week from ViiV Healthcare. ViiV’s dolutegravir is a potent integrase inhibitor with a high barrier to resistance.